International Clinical Trial: Randomized Controlled Trial of IL-1 Monoclonal Antibody vs. Colchicine for the Prophylaxis of Gout Flares During Urate-Lowering Therapy (ULT)

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133686) titled 'Randomized Controlled Trial of IL-1 Monoclonal Antibody vs. Colchicine for the Prophylaxis of Gout Flares During Urate-Lowering Therapy (ULT)' on Sept. 30.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Beijing Hospital

Condition: Prophylaxis of Gout Flares During Urate-Lowering Therapy (ULT)

Intervention: colchicine group:Colchicine 0.5 mg PO QD should be continued through week 12. In clinical practice, for patients with frequent recurrent flares, a dosage of 1 mg daily

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-10-08

Target Sample Size: colc...